

---

## DEFINITIONS

---

*In this document, unless the context otherwise requires, the following terms shall have the meanings set out below.*

“Acepodia”	Acepodia Biotechnologies, Ltd. (育世博生物科技股份有限公司), a limited liability company established under the laws of Taiwan on June 19, 2017, which is an Independent Third Party
“Additional Series A Preferred Share Purchase Agreement”	the share purchase agreement entered into between our Company and certain of its subsidiaries, among others, ARCH Venture Fund IX Overage, L.P. and ARCH Venture Fund IX, L.P. dated May 16, 2018
“Aeon Beijing”	Aeon Therapeutics (Beijing) Limited* (頤昂生物科技(北京)有限公司), a limited liability company established under the laws of the PRC on March 8, 2017, and one of the Company’s subsidiaries
“Aeon Wuhan”	Wuhan Guanggu Aeon Therapeutics Limited* (武漢光谷頤昂生物科技有限公司), a limited liability company established under the laws of the PRC on August 28, 2018, and one of the Company’s subsidiaries
“affiliate(s)”	with respect to any specified person, any other person, directly or indirectly, controlling or controlled by or under direct or indirect common control with such specified person
“Articles” or “Articles of Association”	the seventh amended and restated articles of association of the Company adopted on October 14, 2020 with effect from the [REDACTED], a summary of which is set out in the section headed “Appendix IV — Summary of the Constitution of the Company and Cayman Companies Law” to this document
“ASEAN”	the Association of Southeast Asian Nations, whose member states for the purpose of this document only means Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam

---

## DEFINITIONS

---

“Asset Purchase Agreement”	the asset purchase agreement entered into between our Company, JWS Therapeutics and Syracuse Cayman dated June 30, 2020
“associate(s)”	has the meaning ascribed to it under the Listing Rules
“Audit Committee”	a committee of the Board established by the Board for the purpose of overseeing the accounting and financial reporting processes of our Company and audits of the financial information of our Company
“BCMA License Agreement”	the license agreement entered into between our Company and Juno dated April 11, 2019
“Board” or “Board of Directors” or “our Board”	the board of Directors of the Company
“Bristol Myers Squibb”	Bristol Myers Squibb Company, a company incorporated in Delaware, the United States on August 11, 1933 and whose shares are listed on the New York Stock Exchange (NYSE: BMY), and parent company of Celgene and Juno
“Business Day”	any day (other than a Saturday, Sunday or public holiday) on which banks in Hong Kong are generally open for business
“CAGR”	compound annual growth rate
“Cayman Companies Law” or “Companies Law”	the Companies Law, Cap. 22 (Law 3 of 1961) of the Cayman Islands, as amended or supplemented from time to time
“Cayman Registrar”	the Registrar of Companies of the Cayman Islands
“CCASS”	the Central Clearing and Settlement System established and operated by HKSCC
“CCASS Clearing Participant”	a person admitted to participate in CCASS as a direct participant or a general clearing participant
“CCASS Custodian Participant”	a person admitted to participate in CCASS as a custodian participant

---

## DEFINITIONS

---

“CCASS [REDACTED]”	the application for the Hong Kong [REDACTED] to be issued in the name of HKSCC Nominees and deposited directly into CCASS to be credited to your or a designated CCASS Participant’s stock account through causing HKSCC Nominees to apply on your behalf, including by (i) instructing your broker or custodian who is a CCASS Clearing Participant or a CCASS Custodian Participant to give electronic application instructions via CCASS terminals to apply for the Hong Kong [REDACTED] on your behalf, or (ii) if you are an existing CCASS Investor Participant, giving electronic application instructions through the CCASS Internet System ( <a href="https://ip.ccass.com">https://ip.ccass.com</a> ) or through the CCASS Phone System (using the procedures in HKSCC’s “An Operating Guide for Investor Participants” in effect from time to time). HKSCC can also input electronic application instructions for CCASS Investor Participants through HKSCC’s Customer Service Centre by completing an input request
“CCASS Investor Participant”	a person admitted to participate in CCASS as an investor participant, who may be an individual or joint individuals or a corporation
“CCASS Participant”	a CCASS Clearing Participant, a CCASS Custodian Participant or a CCASS Investor Participant
“Celgene”	Celgene Corporation, a company incorporated in Delaware, the United States on April 17, 1986, a wholly-owned subsidiary of Bristol Myers Squibb and parent company of Juno
“CEO”	the chief executive officer of our Group
“China” or “the PRC”	the People’s Republic of China and for the purposes of this document only, except where the context requires otherwise, references to China or the PRC exclude Hong Kong, Macau and Taiwan

---

## DEFINITIONS

---

“Circular 7”	Announcement on Several Issues Concerning Enterprise Income Tax for Indirect Transfer of Assets by Non-Resident Enterprises (國家稅務總局關於非居民企業間接轉讓財產企業所得稅若干問題的公告), issued by SAT on February 3, 2015
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Companies (Winding Up and Miscellaneous Provisions) Ordinance”	the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Company”, “our Company”, or “the Company”	JW (Cayman) Therapeutics Co. Ltd, an exempted company with limited liability incorporated under the laws of the Cayman Islands on September 6, 2017
“Compliance Advisor”	Guotai Junan Capital Limited
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“connected transaction(s)”	has the meaning ascribed to it under the Listing Rules
“core connected person(s)”	has the meaning ascribed to it under the Listing Rules
“Core Product Candidate”	relma-cel, the designated “core product” as defined under Chapter 18A of the Listing Rules
“Consolidated Affiliated Entities”	the entities we control through the Contractual Arrangements, namely Shanghai Ju Ming and its subsidiaries Shanghai Ming Ju and Suzhou Ming Ju
“Contractual Arrangements”	a series of contractual arrangements entered into among Shanghai Ju Ming, JW Shanghai and the Registered Shareholders for control over the Consolidated Affiliated Entities, details of which are described in the section headed “Contractual Arrangements” in this document

---

## DEFINITIONS

---

“COVID-19”	an infectious disease caused by the most recently discovered coronavirus (severe acute respiratory syndrome coronavirus 2), first reported in December 2019
“Director(s)”	the director(s) of the Company
“Dr. Li”	Dr. Yiping James Li, our executive Director, chairman of the Board and CEO
“Dr. Li 2020 GRAT”	an [irrevocable grantor retained annuity trust] set up by Dr. Li on October 13, 2020 under the laws of the State of California, the United States for the benefit of himself and his family members, of which Dr. Li serves as the trustee
“EIT”	enterprise income tax
“EIT Law”	the PRC Enterprise Income Tax Law, promulgated on March 16, 2007 and latest amended on December 29, 2018
“Eureka”	Eureka Therapeutics, Inc., a privately held company incorporated under the laws of California, the United States on February 14, 2006, and re-incorporated under the laws of Delaware, the United States on March 5, 2018, being a minority shareholder of our Substantial Shareholder, Syracuse Cayman
“Eureka Beijing”	Eureka (Beijing) Biotechnology Co., Ltd* (優瑞科(北京)生物技術有限公司), a limited liability company established under the laws of the PRC on April 2, 2007, and one of the Company’s subsidiaries
“Eureka License Agreement”	the license agreement entered into between Eureka, Eureka Therapeutics (Cayman), Inc. and Syracuse Cayman dated June 30, 2020
“Extreme Conditions”	extreme conditions caused by a super typhoon as announced by the government of Hong Kong
“Frost & Sullivan”	Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., a global market research and consulting company, which is an independent industry consultant

---

## DEFINITIONS

---

“Frost & Sullivan Report”	an independent market research report commissioned by us and prepared by Frost & Sullivan for the purpose of this document
[REDACTED]	the Hong Kong [REDACTED] and the [REDACTED]
[REDACTED]	the [REDACTED] to be completed by the [REDACTED] Provider, [REDACTED]
“Group”, “our Group”, “the Group”, “we”, “us”, or “our”	the Company, its subsidiaries and the Consolidated Affiliated Entities from time to time
“HKSCC”	Hong Kong Securities Clearing Company Limited
“HKSCC Nominees”	HKSCC Nominees Limited, a wholly-owned subsidiary of HKSCC
“Hong Kong” or “HK”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong dollars” or “HK dollars” or “HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong [REDACTED]”	the [REDACTED] Shares (subject to adjustment as described in the section headed “Structure of the [REDACTED]” in this document) being [REDACTED] at the [REDACTED] pursuant to the Hong Kong [REDACTED]
“Hong Kong [REDACTED]”	the [REDACTED] of the Hong Kong [REDACTED] for [REDACTED], on the terms and subject to the conditions described in this document, as further described in the section headed “Structure of the [REDACTED] — The Hong Kong [REDACTED]” in this document
“Hong Kong Securities and Futures Ordinance” or “SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time

---

## DEFINITIONS

---

“Hong Kong [REDACTED]”	[REDACTED]
“Hong Kong Stock Exchange” or “Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Hong Kong [REDACTED]”	the [REDACTED] of the Hong Kong [REDACTED] listed in the section headed “[REDACTED] — Hong Kong [REDACTED]” in this document
“Hong Kong [REDACTED]”	the Hong Kong [REDACTED] dated [REDACTED], 2020 relating to the Hong Kong [REDACTED] entered into by our Company, the [REDACTED] and the Hong Kong [REDACTED], as further described in the section headed “Structure of the [REDACTED] — The Hong Kong [REDACTED]” in this document
“IFRS”	International Accounting Standards, International Financial Reporting Standards, amendments and the related interpretations issued by the International Accounting Standards Board
“Independent Third Party(ies)”	any entity or person who is not a connected person of the Company within the meaning ascribed thereto under the Listing Rules
“International [REDACTED]”	the [REDACTED] Shares being [REDACTED] in the [REDACTED] together with, where relevant, any additional Shares which may be issued by us pursuant to the exercise of the [REDACTED], subject to adjustment as described in the section headed “Structure of the [REDACTED]” in this document

---

## DEFINITIONS

---

[REDACTED] the [REDACTED] of the [REDACTED] Shares at the [REDACTED] outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and in the United States to QIBs only in reliance on Rule 144A or any other available exemption from the registration requirement under the U.S. Securities Act, in each case on and subject to the terms and conditions of the [REDACTED], as further described in the section headed “Structure of the [REDACTED]” in this document

[REDACTED] the [REDACTED] of the [REDACTED]

[REDACTED] the [REDACTED] relating to the [REDACTED] to be entered into among our Company and the [REDACTED] on or about the [REDACTED], as further described in the section headed “[REDACTED]” in this document

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

“Joint Sponsors” Goldman Sachs (Asia) L.L.C. and UBS Securities Hong Kong Limited



---

## DEFINITIONS

---

“Juno”	Juno Therapeutics, Inc., a company incorporated in Delaware, the United States on August 5, 2013 under its former name, FC Therapeutics, Inc., a wholly-owned subsidiary of Celgene which is in turn wholly-owned by Bristol Myers Squibb, and is one of our Substantial Shareholders
“Juno Settlement Shares”	the [4,665,530] Shares (as adjusted after Share Subdivision) to be issued to Juno at nil consideration upon exercise of warrant by Juno pursuant to the BCMA License Agreement as part of the upfront payment
“JW Hong Kong”	JW (Hong Kong) Therapeutics Limited, a limited company established under the laws of Hong Kong on October 3, 2017, and one of the Company’s subsidiaries
“JW R&D Shanghai”	JW Therapeutics R&D (Shanghai) Co., Ltd (上海藥明巨諾生物醫藥研發有限公司), a limited liability company established under the laws of the PRC on December 5, 2018, and one of the Company’s subsidiaries
“JW Shanghai”	JW Therapeutics (Shanghai) Co., Ltd. (上海藥明巨諾生物科技有限公司), a limited liability company established under the laws of the PRC on February 18, 2016, and one of the Company’s subsidiaries
“JW Suzhou”	JW Therapeutics (Suzhou) Co., Ltd. (蘇州藥明巨諾生物科技有限公司), a limited liability company established under the laws of the PRC on September 12, 2018, and one of the Company’s subsidiaries
“JWS Therapeutics”	JWS Therapeutics Investment Co., Ltd. an exempted company incorporated in the Cayman Islands with limited liability on June 19, 2020, and one of the Company’s subsidiaries
“KOL(s)”	key opinion leader(s)
“Latest Practicable Date”	October 16, 2020, being the latest practicable date or ascertaining certain information in this document before its publication

---

## DEFINITIONS

---

[REDACTED]	[REDACTED]
“Listing Committee”	the listing committee of the Stock Exchange
[REDACTED]	[REDACTED]
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
“Main Board”	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operates in parallel with the Growth Enterprise Market of the Stock Exchange
“Macau”	the Macau Special Administrative Region of the PRC
“Memorandum” or “Memorandum of Association”	the seventh amended and restated memorandum of association of the Company adopted on October 14, 2020 with effect from the [REDACTED], a summary of which is set out in the section headed “Appendix IV — Summary of the Constitution of the Company and Cayman Companies Law” to this document
“MOFCOM”	Ministry of Commerce of the PRC (中華人民共和國商務部)
“MOHRSS”	Ministry of Human Resources and Social Security of the PRC (中華人民共和國人力資源和社會保障部)
“NDRC”	National Development and Reform Commission of the PRC (中華人民共和國國家發展和改革委員會)
“NHC”	National Health Commission of the PRC (中華人民共和國國家衛生健康委員會)

---

## DEFINITIONS

---

“NMPA”	National Medical Products Administration (國家藥品監督管理局) and its predecessor, China Food and Drug Administration (國家食品藥品監督管理總局)
“NPC”	National People’s Congress of the PRC (全國人民代表大會)
[REDACTED]	the final price per [REDACTED] (exclusive of brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) at which Hong Kong [REDACTED] are [REDACTED], to be determined in the manner further described in “Structure of the [REDACTED] — [REDACTED]” in this document
[REDACTED]	the Hong Kong [REDACTED] and the International [REDACTED] together with, where relevant, [REDACTED] pursuant to the exercise of the [REDACTED]
[REDACTED]	the option expected to be granted by our Company to the [REDACTED] (on behalf of the [REDACTED]) under the [REDACTED] pursuant to which our Company may be required by the [REDACTED] to allot and issue up to [REDACTED] additional Shares, representing approximately [REDACTED] of the [REDACTED] initially available under the [REDACTED], at the [REDACTED] to cover [REDACTED] in the [REDACTED], details of which are described in the section headed “Structure of the [REDACTED]” in this document
[REDACTED]	up to [REDACTED] Shares which our Company may be required to [REDACTED] at the [REDACTED] pursuant to the [REDACTED]
“Post-[REDACTED] Restricted Share Unit Scheme”	the Post-[REDACTED] Restricted Share Unit Scheme adopted by the Company on October 14, 2020, the principal terms of which are set out in the section headed “Appendix V — Statutory and General Information — D. Share Incentivization Schemes — 2. Restricted Share Unit Schemes” to this document

---

## DEFINITIONS

---

“Post-[REDACTED] Share Incentivization Scheme”	the Post-[REDACTED] Share Incentivization Scheme adopted by the Company on October 14, 2020, the principal terms of which are set out in the section headed “Appendix V — Statutory and General Information — D. Share Incentivization Schemes — 3. Post-[REDACTED] Incentivization Scheme” to this document
“PRC Government” or “State”	the central government of the PRC, including all political subdivisions (including provincial, municipal and other regional or local government entities) and its organs or, as the context requires, any of them
“PRC Legal Advisor”	Tian Yuan Law Firm
“Pre-[REDACTED] Incentivization Scheme”	the Pre-[REDACTED] Incentivization Scheme adopted by the Company on September 4, 2019, the principal terms of which are set out in the section headed “Appendix V — Statutory and General Information — D. Share Incentivization Schemes — 1. Pre-[REDACTED] Incentivization Schemes” to this document
“Pre-[REDACTED] Investment(s)”	the pre-[REDACTED] investment(s) in the Company undertaken by the Pre-[REDACTED] Investors, details of which are set out in the section headed “History, Development and Corporate Structure” in this document
“Pre-[REDACTED] Investors”	the Series A1 Investors, Series A2 Investors, Series X Investors and Series B Investors and Syracuse Cayman
“Preferred Share(s)”	the Series A1 Preferred Shares, Series A2 Preferred Shares, Series X Preferred Shares and Series B Preferred Shares
[REDACTED]	the date, expected to be on or about [REDACTED], 2020, on which the [REDACTED] will be determined and, in any event, not later than [REDACTED], 2020
“QIBs”	qualified institutional buyers within the meaning of Rule 144A

---

## DEFINITIONS

---

“Registered Shareholders”	the registered shareholders of Shanghai Ju Ming, being Ms. Jing Lv (呂晶), an employee of our Group and Ms. Xing Gao (高星), our non-executive Director, as at the Latest Practicable Date
“Regulation S”	Regulation S under the U.S. Securities Act
“Remuneration Committee”	a committee of the Board established by the Board to discharge the Board’s responsibilities relating to the remuneration of Directors and executive officers of our Company
“Restricted Share Unit Scheme”	the Restricted Share Unit Scheme adopted by the Company on September 4, 2019, the principal terms of which are set out in the section headed “Appendix V — Statutory and General Information — D. Share Incentivization Schemes — 2. Restricted Share Unit Schemes” to this document
“Restricted Share Unit Schemes”	the Restricted Share Unit Scheme and the Post-[REDACTED] Restricted Share Unit Scheme
“RMB” or “Renminbi”	Renminbi, the lawful currency of China
“RSU(s)”	the restricted share unit(s) granted pursuant to the Restricted Share Unit Scheme
“Rule 144A”	Rule 144A under the U.S. Securities Act
“SAFE”	State Administration of Foreign Exchange of the PRC (中華人民共和國外匯管理局)
“SAT”	State Administration of Taxation of the PRC (中華人民共和國國家稅務總局)
“Series A Preferred Share Purchase Agreement”	the share purchase agreement entered into between our Company and certain of its subsidiaries, among others, the then Series A1 Investors and the then Series A2 Investors dated February 13, 2018
“Series A1 Investors”	the holders of Series A1 Preferred Shares
“Series A1 Preferred Shares”	the series A1 preferred shares of the Company

---

## DEFINITIONS

---

“Series A2 Investors”	the holders of Series A2 Preferred Shares
“Series A2 Preferred Shares”	the series A2 preferred shares of the Company
“Series B Investors”	the holders of Series B Preferred Shares
“Series B Preferred Shares”	the series B preferred shares of the Company
“Series B Preferred Share Purchase Agreement”	the share purchase agreement entered into between our Company and certain of its subsidiaries and among others, the then Series B Investors dated May 13, 2020
“Series X Investor”	the holder of Series X Preferred Shares
“Series X Preferred Shares”	the series X preferred shares of the Company
“Series X Preferred Share Purchase Agreement”	the share purchase agreement entered into between our Company and certain of its subsidiaries and among others, Juno dated November 20, 2019
“SFC”	the Securities and Futures Commission of Hong Kong
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended or supplemented from time to time
“Shanghai Ming Ju”	Shanghai Ming Ju Biotechnology Co., Ltd.* (上海明聚生物科技有限公司), a limited liability company established under the laws of the PRC on August 30, 2017 and our Consolidated Affiliated Entity
“Shanghai Ju Ming”	Shanghai Ju Ming Medical Technology Co., Ltd.* (上海炬明醫療技術有限公司), a limited liability company established under the laws of the PRC on July 10, 2017 and our Consolidated Affiliated Entity
“Share(s)”	ordinary share(s) in the capital of the Company with nominal value of US\$0.00001 each
“Share Incentivization Schemes”	our Pre-[REDACTED] Incentivization Scheme, Restricted Share Unit Schemes and Post-[REDACTED] Incentivization Scheme

---

## DEFINITIONS

---

“Shareholder(s)”	holder(s) of Shares
“Shareholders’ Agreement”	the fourth amended and restated shareholders agreement entered into between the Company and the Pre-[REDACTED] Investors dated June 30, 2020
“Share Subdivision”	the further subdivision of issued and unissued authorized shares of our Company with par value of US\$0.0001 each into 10 shares of the corresponding class with par value of US\$0.00001 each
“Sophisticated Investor(s)”	has the meaning ascribed to it under Guidance Letter HKEX-GL92-18 issued by the Stock Exchange and refers to Temasek Holdings (Private) Limited, Mirae Asset Securities (HK) Ltd., Mirae Asset - Naver Asia Growth Investment Pte. Ltd., Mirae Asset - Celltrion New Growth Fund, Mirae Asset Capital Co., Ltd and Sequoia Capital China Venture Fund VI, L.P.
[REDACTED]	[REDACTED]
“State Council”	the PRC State Council (中華人民共和國國務院)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed to it under section 15 of the Companies Ordinance
“Substantial Shareholder(s)”	has the meaning ascribed to it under the Listing Rules
“Suzhou Ming Ju”	Suzhou Ming Ju Biotechnology Co., Ltd.* (蘇州明聚生物科技有限公司), a limited liability company established under the laws of the PRC on August 30, 2018 and our Consolidated Affiliated Entity
“Syracuse Acquisition”	the acquisition and assumption of Syracuse Cayman’s assets and liabilities under the Asset Purchase Agreement

---

## DEFINITIONS

---

“Syracuse Cayman”	Syracuse Biopharma (Cayman) Ltd., a limited liability company established under the laws of Cayman Islands on December 7, 2017 under its former name, Warrior Biopharma (Cayman) Ltd., and one of our Substantial Shareholders
“Syracuse Holdback Shares”	the maximum number of [5,132,467] Shares (as adjusted after Share Subdivision) to be issued to Syracuse Cayman pursuant to the Asset Purchase Agreement to settle US\$10.5 million for any future adjustments with deduction, including net working capital adjustment and taxes to be paid under the Asset Purchase Agreement
“Syracuse Hong Kong”	Syracuse Biopharma (Hong Kong) Limited, a limited liability company established in Hong Kong on June 7, 2018, and one of the Company’s subsidiaries
“Syracuse Jiangsu”	Syracuse Biopharma (Jiangsu) Co., Ltd.* (賽諾思遠生物科技(江蘇)有限公司), a limited liability company established under the laws of the PRC on September 18, 2018, and one of the Company’s subsidiaries
“Takeovers Code”	The Code on Takeovers and Mergers issued by the SFC, as amended, supplemented or otherwise modified from time to time
“Track Record Period”	the two financial years of the Company ended December 31, 2018 and 2019, and the six months ended June 30, 2020
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
“United States”, “U.S.” or “US”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“US dollars”, “U.S. dollars” or “US\$”	United States dollars, the lawful currency of the United States of America



---

## DEFINITIONS

---

“U.S. FDA” or “FDA”	the U.S. Food & Drug Administration of the U.S. Department of Health and Human Services
“U.S. Securities Act”	United States Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder
“Wei Zexi Incident”	an incident leading up to the regulatory changes in China’s cellular immunotherapy industry in May 2016 involving the death of a late-stage synovial sarcoma patient who received treatment using certain cellular immunotherapy products related to germline gene therapy which is unrelated to our Company and not the nature of the Company’s business
[REDACTED]	the application for Hong Kong [REDACTED] to be issued in the applicant’s own name by submitting applications online through the designated website of [REDACTED] Provider at <a href="http://www.[REDACTED].com.hk">www.[REDACTED].com.hk</a>
“[REDACTED] Provider”	[REDACTED]
“WuXi AppTec” or “WXAT”	WuXi AppTec Co., Ltd. (無錫藥明康德新藥開發股份有限公司), a joint stock company with limited liability incorporated under the laws of PRC in December, 2000 and whose H shares are listed on the Stock Exchange (SEHK: 2359) and A shares are listed on the Shanghai Stock Exchange (SSE: 603259)
“WuXi AppTec Group”	WuXi AppTec and its affiliates
“WXAT HK”	WuXi AppTec (Hong Kong) Holding Limited, a limited liability company incorporated under the laws of Hong Kong on January 6, 2015, and an indirectly wholly-owned subsidiary of WXAT, and is one of our Substantial Shareholders
“WXAT Shanghai”	WuXi AppTec (Shanghai) Co., Ltd. (上海藥明康德新藥開發股份有限公司), a company incorporated under the laws of PRC on April 2, 2002, and a directly wholly-owned subsidiary of WXAT, and directly owns WXAT HK

---

## DEFINITIONS

---

“%” per cent

*Unless otherwise expressly stated or the context otherwise requires, all data in this document is as of the date of this document.*

*The English names of the PRC entities, PRC laws or regulations, and the PRC governmental authorities referred to in this document are translations from their Chinese names and are for identification purposes. If there is any inconsistency, the Chinese names shall prevail.*

*Certain amounts and percentage figures included in this document have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation of the figures preceding them.*